NEXTCURE
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.
NEXTCURE
Industry:
Biopharma Biotechnology Health Care
Founded:
2015-01-01
Address:
Beltsville, Maryland, United States
Country:
United States
Website Url:
http://www.nextcure.com
Total Employee:
51+
Status:
Active
Contact:
(240)264-1250
Email Addresses:
[email protected]
Total Funding:
310 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt WordPress Font Awesome Domain Not Resolving Wordpress Plugins
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Lilly Asia Ventures
Lilly Asia Ventures investment in Series B - NextCure
Surveyor Capital
Surveyor Capital investment in Series B - NextCure
Pfizer
Pfizer investment in Series B - NextCure
Eli Lilly
Eli Lilly investment in Series B - NextCure
Ping An Ventures
Ping An Ventures investment in Series B - NextCure
Sofinnova Investments
Sofinnova Investments investment in Series B - NextCure
OrbiMed
OrbiMed investment in Series B - NextCure
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - NextCure
Hillhouse Capital Group
Hillhouse Capital Group investment in Series B - NextCure
ArrowMark Partners
ArrowMark Partners investment in Series B - NextCure
Key Employee Changes
| Date | New article |
|---|---|
| 2021-01-15 | NextCure hires Celgene vet as CMO; José Vega leaves Merck to become Moderna’s chief safety officer |
Official Site Inspections
http://www.nextcure.com
- Host name: 104.26.12.204
- IP address: 104.26.12.204
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "NextCure"
NextCure, Inc.
NextCure will emerge as a global leader in developing novel immunomedicines and cures through our commitment to scientific innovation, patient needs, and organizational excellence.See details»
About Us >> Background – NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer patients through the use of differentiated mechanisms of action and antibody …See details»
NextCure, Inc. - LinkedIn
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by...See details»
NextCure - Crunchbase Company Profile & Funding
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and …See details»
NextCure, Inc. - AnnualReports.com
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.See details»
NextCure Company Profile - Office Locations, Competitors, …
Sep 24, 2024 · NextCure is a biopharmaceutical company focused on discovering and developing next-generation immuno-oncology-based drugs. The Company offers find-io platform which …See details»
Org Chart NextCure - The Official Board
The organizational chart of NextCure displays its 17 main executives including Michael Richman, Steven Cobourn and Timothy Mayer Toggle navigation The Official Board SearchSee details»
NextCure, Inc. (NXTC) Company Profile & Overview - Stock Analysis
May 9, 2019 · NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related …See details»
Product Development – NextCure, Inc.
NextCure has developed a large repertoire of function-based screening and translational methods to develop therapeutics that improve immune function. This includes overcoming resistance …See details»
NextCure Provides Business Update and Reports Fourth Quarter …
BELTSVILLE, Md., March 03, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first …See details»
NextCure Provides Business Update and Reports Full Year 2023 …
Mar 21, 2024 · “Clinical data generated in 2023 enabled us to objectively assess each program and set our priorities for 2024. Based on that assessment, we will prioritize NC410 combo and …See details»
NextCure Provides Business Update and Reports Full Year 2022 …
Mar 2, 2023 · NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune …See details»
NextCure Announces New Appointments to its Board of Directors
BELTSVILLE, Md., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first …See details»
NextCure, Inc., New Immuno-Oncology Firm Announces $67 …
Jan 6, 2016 · Germantown, Md. and New Haven, Ct., January 6, 2016 – NextCure, Inc., a newly formed biopharmaceutical company focused on the discovery and development of new …See details»
NextCure Provides Business Update and Reports Third Quarter …
Nov 2, 2023 · NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune …See details»
NextCure to lay off 37% of staff, dial back research plans
Mar 21, 2024 · Cancer immunotherapy developer NextCure is laying off 37% of its staff and streamlining its research plans, the company said Thursday. Alongside its 2023 earnings, the …See details»
NextCure Provides Year-End Clinical Pipeline Updates - Yahoo …
Dec 14, 2023 · NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune …See details»
NextCure Provides Update and Reports Third Quarter 2022 …
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.See details»
Cancer cells impair monocyte-mediated T cell stimulation to evade ...
1 day ago · The tumour microenvironment is programmed by cancer cells and substantially influences anti-tumour immune responses1,2. Within the tumour microenvironment, CD8+ T …See details»
NextCure Reports Preclinical Data for LNCB74 and Additional …
BELTSVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first …See details»